Affiliation:
1. Main Military Clinical Hospital named after N.N. Burdenko, Ministry of Defense of Russia
2. Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Abstract
Understanding the molecular biological basis of chronic lymphocytic leukemia (CLL) pathogenesis and stratification of patients into risk groups has now led to significant advances in treatment. New targeted drugs with different mechanisms of action (bruton’s tyrosine kinase inhibitors, bCL-2 inhibitors, pI3K inhibitors) have significantly improved the prognosis of high-risk CLL patients. In some CLL cases the nodular tumor component can change to a more aggressive subtype of lymphoma (often diffuse large b-cell) with preservation of the small-cell leukemic component with the CLL phenotype (Richter’s syndrome), usually characterized by rapid progression and poor prognosis. The issue of treatment efficacy in patients with Richter’s syndrome still remains unresolved. The results of new drugs clinical trials are often contradictory and cannot yet be recommended for routine use in clinical practice. The low incidence of Richter’s syndrome, the lack of a unified view of the pathogenesis and therapy approaches make the search for effective drugs an urgent task, so each clinical observation is of undoubted interest.A clinical case of CLL patient with unfavorable molecular cytogenetic risk and transformation into diffuse large b-cell lymphoma (Richter’s syndrome) is presented. The combined use of bCL-2 inhibitors (venetoclax) and pI3K (duvelisib) led to the achievement of partial remission followed by a gradual increase in the positive antitumor effect.
Publisher
Publishing House ABV Press
Reference39 articles.
1. Hallek M. Chronic lymphocytic leukemia. Klinicheskaya onkogematologiya = Clinical oncohematology 2010;3(1):101–2. (In Russ.).
2. Zakharova A.I., Obukhova T.N., Lorie Yu.Yu. et al. Cytogenetic aberrations in chronic Bcell lymphocytic leukemia and their relationship with clinical and biological features and disease prognosis. Terapevticheskiy arkhiv = Therapeutic archive 2006;78(7)57–62. (In Russ.).
3. Reindl L., Bacher U., Dicker F. et al. Biological and clinical characterization of recurrent 14q deletions in CLL and other mature Bcell neoplasms. Br J Haematol 2010;151(1):25–36. DOI: 10.1111/j.13652141.2010.08299.
4. Nikitin E.A., Severina N.A., Obukhova T.N. et al. TP53 gene aberrations in patients with chronic lymphocytic leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(4):316–22. (In Russ.).
5. Lin K.I., Tam C.S., Keating M.J. et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood 2009;113(14):3168–71. DOI: 10.1182/blood200810184853